Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients

• Status: Completed
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if Revlimid will help maintain patients with acute myeloid leukemia in remission.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Health Network, Toronto
• Collaborator: Celgene Corporation
• Treatments: Lenalidomide

Criteria

Inclusion Criteria:

• Diagnosis of Acute myeloid leukemia in remission.

• Able to take aspirin 81mgs daily.

Exclusion Criteria:

• Pregnant or breast feeding females.

• Known hypersensitivity to thalidomide.

• Any prior use of lenalidomide.